Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neotherapuetics possibly has a breakthrough drug - NEOT -- Ignore unavailable to you. Want to Upgrade?

To: GC who wrote (178)	8/13/2001 11:17:43 AM
From: tuck	Read Replies (1) \| Respond to of 204

This won't translate without my help, but NEOT decided to use big, bold lettering for the first several lines. As if they'd cured a disease or something. Not yet. Looks like this: >>NeoTherapeutics Repurchases NeoGene Convertible Financing Overhang from potential conversion eliminated BULLETIN!! BULLETIN!! NeoTherapeutics will hold a telephone conference call tomorrow, Aug. 14, 2001 starting at 10:00 A.M. (EDT). Alvin J. Glasky, Ph.D., Chairman; Rajesh C. Shrotriya, Ph.D., President; and, Sam Gulko, Senior Vice President, Finance and Chief Financial Officer, will discuss issues and answer questions relating to this news release. Those wishing to participate should call 888-552-7850 at approximately 9:50 A.M. (EDT). A replay of this conference call will be available on the Company's website at www.neotherapeutics.com. IRVINE, Calif., Aug. 13 /PRNewswire/ -- NeoTherapeutics, Inc. (Nasdaq: NEOT - news, NEOTW - news) announced today that the Company has reached an agreement to repurchase $5 million of convertible preferred stock in its NeoGene Technologies, Inc. subsidiary from two institutional investors. ``The redemption of this $5 million convertible financing is an important step in enhancing our financial position,'' stated Sam Gulko, Senior Vice President, Finance and Chief Financial Officer of NeoTherapeutics. ``We have established relationships with several Wall Street investment banking firms, and, going forward, are committed to seeking financings with long-term oriented investors that do not contain floating conversion features or reset provisions.'' ``We are pleased that these institutions have agreed to the repurchase of their NeoGene preferred stock,'' said Alvin J. Glasky, Ph.D., Chairman and Chief Executive Officer of NeoTherapeutics. ``We hope that this buy-back will alleviate the concerns investors have had about the potential incentive for a conversion of these preferred shares into NeoTherapeutics common stock to occur at a low price. The Company has a significant number of important milestones that it expects to achieve over the next few months, and the elimination of this NeoGene financing simplifies the stock structure of the Company.'' The convertible preferred shares were issued on September 21, 2001, and gave the investors the option to exchange their NeoGene preferred stock into NeoTherapeutics preferred stock and then convert into NeoTherapeutics common stock based on the market price of the Company's stock prior to conversion.<< snip Cheers, Tuck